Loading...
•
Dec 31, 2021
Mersana Q4 2021 Earnings Report
Mersana's financial position strengthened with strategic partnerships and clinical advancements.
Key Takeaways
Mersana Therapeutics reported its Q4 2021 financial results, highlighting progress in its UpRi development plan, advancements in its ADC pipeline, and a strengthened financial position through strategic partnerships and financing activities.
UpRi development on track for potential BLA submission in 2023 based on UPLIFT data.
UP-NEXT trial to initiate in Q2 2022, and UPGRADE on track for 2H 2022 interim data readout.
XMT-1660 and XMT-2056 expected to enter clinic mid-2022.
Janssen collaboration validates Dolasynthen platform and ADC innovation.
Forward Guidance
Mersana is focused on advancing clinical trials, expanding its ADC pipeline, and leveraging its technology platforms for strategic partnerships.
Positive Outlook
- Completing enrollment for UPLIFT trial in Q3 2022.
- Initiating UP-NEXT trial in Q2 2022.
- Anticipating interim data readout from UPGRADE trial in 2H 2022.
- Advancing XMT-1660 and XMT-2056 into the clinic by mid-2022.
- Leveraging ADC expertise and Dolasynthen platform through Janssen collaboration.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...